|
|
SE-112 76
Stockholm, SE-112 76 Sweden
phone:+46 8 697 20 00
fax:
|
|
| Symbol |
SEK |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.biovitrum.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Drug research with expertise in the fields of obesity, diabetes and inflammation. |
|
| Management |
| Martin Nicklasson, CEO; G?ran Arvidson, CFO; Erik Kinnman, VP Investor Relations and Public Affairs, Chief Strategic Officer; Hans ?rstr?m, SVP Commercial Operations and Corporate Development; Peter Edman, CSO; Maria Berggren, Head of Human Resources; Fredrik Berg, General Counsel and SVP Legal & Intellectual Property |
| |
|
|
|
|
|
|
|
| Keywords |
| obesity, Diabetes, blood sugar, diabetic, metabolic, insulin, inflammation, cancer, eye, disease, drug, drugs |
|
|
|
| Description |
|
Biovitrum AB combines research and development with commercial operations. Biovitrum has in-house research operations including cutting-edge expertise in the fields of obesity, diabetes and inflammation. The influx of new projects from its own research is complemented by strategic acquisitions, partnerships and alliances. Consequently, Biovitrum's project portfolio also includes projects within the fields of cancer and eye disease. |
|
|
| Status |
| Biovitrum has operations in Stockholm and Uppsala in Sweden and in Cambridge in the UK. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
